Stem Cell Clinic

Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Projected to Grow Massively in Near Future – The Daily Philadelphian

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market report gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take market research report service which has become enough vital in todays market place.

The report represents a professional and all-inclusive study of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis. This market report explains an array of aspects of the market analysis which todays businesses call for. It has become the requisite of this rapidly changing marketplace to take up such Autologous Stem Cell and Non-Stem Cell Based Therapies Market report that makes aware of the market conditions around.

Get Free Sample PDF (including COVID19 Impact Analysis) of Autologous Stem Cell and Non-Stem Cell Based Therapies Market[emailprotected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Insights:

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

This report examines all the key factors influencing the growth of Autologous Stem Cell and Non-Stem Cell Based Therapies market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Autologous Stem Cell and Non-Stem Cell Based Therapies market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Prominent Key Players Covered in the report:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics:

The Autologous Stem Cell and Non-Stem Cell Based Therapies report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Major Regions as Follows:

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

How Does This Market Insights Help?

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

Reasons to Purchase this Report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries includes Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail: [emailprotected]

Link:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Projected to Grow Massively in Near Future - The Daily Philadelphian

Global Live Cell Imaging Markets, 2020-2025 – Growing Adoption of High-Content Screening Techniques in Drug Discovery – Yahoo Finance UK

Bloomberg

(Bloomberg) -- Stocks slumped and Treasuries rallied as a resurgence in coronavirus cases added to concern about tougher restrictions that could slow down the economic recovery without further stimulus.The S&P 500 sank as much as 1.4% as New York City -- the early epicenter of the pandemic in the U.S. -- prepared for the possibility of closing its schools while Chicago issued an advisory urging residents to avoid leaving home except for work and other essential activities. The Trump administration is stepping back from talks on a government relief package and leaving it up to Congress to revive negotiations with House Speaker Nancy Pelosi, according to people familiar with the situation. Majority Leader Mitch McConnell took the first step for the Senate to confirm Judy Shelton as soon as the coming week to the Federal Reserve board, one of President Donald Trumps outstanding two nominations.All major groups in the American equity benchmark retreated, led by declines in energy producers and banks. While the Nasdaq 100 erased earlier gains, it outperformed other benchmarks on bets that tech companies flush with cash will remain as a safety trade. The Russell 2000 index of smaller companies sank.Read: Raging Virus, Fresh Restrictions Bite Budding Rotation TradeThree of the worlds top central bankers warned Thursday that the prospect of a Covid-19 vaccine isnt enough to put an end to the economic challenges created by the pandemic. Coronavirus infections and hospitalizations are rising in 49 U.S. states, compared with a week ago, according to Covid Tracking Project data. Deaths, a lagging indicator, are climbing in 35. And the velocity at which records are being shattered suggests any decline may yet be far off. The U.S. recorded 152,255 new infections on Wednesday as the virus spreads across the nation, with fatalities reaching their highest point since May.The blame seems to be going to the increased cases of Covid-19 in the U.S. and around the world, and the proposed lockdowns that are going along with it, said Matt Maley, chief market strategist at Miller Tabak + Co, referring to the drop in equities. This makes total sense, but we also need to recognize that this is not new news at all. Therefore, we think the real reason for the weakness is the simple fact that the stock market had become overbought on a very short-term basis.JPMorgan Asset Management is cutting its projections for cross-asset returns over the next decade and signaling more pain for 60/40 allocations that have long formed the bedrock of traditional portfolios. Strategists at the firm reduced their estimate for global equities by 1.4 percentage point to 5.1% a year in the next decade, citing elevated valuations in U.S. large caps. They forecast negative inflation-adjusted returns across almost all sovereign bonds over the next 10 to 15 years, with yields remaining low even after rates normalize.U.S. stocks are likely to fall short in their push to break a dot-com era record, according to Chris Kimble, chief executive officer of Kimble Charting Solutions. Kimble analyzed the ratio between the Nasdaq 100 and the Dow Jones Industrial Average in a blog post this week. The ratio climbed as much as 40% this year through Sept. 1, when it reached the highest level since March 2000, according to data compiled by Bloomberg. On Monday and Tuesday, the ratio fell by a combined 7.4%. The two-day drop was the steepest since May 2001.These are some of the main moves in markets:StocksThe S&P 500 Index dipped 1.3% as of 2:47 p.m. New York time.The Stoxx Europe 600 Index decreased 0.9%.The MSCI Asia Pacific Index rose 0.3%.CurrenciesThe Bloomberg Dollar Spot Index climbed 0.1%.The euro climbed 0.2% to $1.1798.The Japanese yen strengthened 0.2% to 105.20 per dollar.BondsThe yield on 10-year Treasuries fell eight basis points to 0.89%.Germanys 10-year yield sank three basis points to -0.54%.Britains 10-year yield slid seven basis points to 0.348%.CommoditiesThe Bloomberg Commodity Index was little changed.West Texas Intermediate crude increased 1% to $41.88 a barrel.Gold rose 0.5% to $1,875.85 an ounce.(An earlier version of the wrap corrected spelling of strategist name in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2020 Bloomberg L.P.

See original here:
Global Live Cell Imaging Markets, 2020-2025 - Growing Adoption of High-Content Screening Techniques in Drug Discovery - Yahoo Finance UK

GLOBAL STEM CELL MARKET FORECAST 2021-2028 – GlobeNewswire

November 11, 2020 09:24 ET | Source: ReportLinker

New York, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL STEM CELL MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p05478235/?utm_source=GNW

MARKET INSIGHTS Stem cells possess remarkable potential, in terms of promoting wound repaid in a paracrine manner and cutaneous tissue regeneration.As mesenchymal stem cells, numerous cell types, embryonic stem cells, epithelial stem cells, resident tissue stem cells, hematopoietic stem cells, and adipose-derived stem cells are presently under extensive investigation.

As a result, this is likely to contribute to the significant growth of the stem cell market. Umbilical cord stem cells as a non-invasive and efficacious alternative source of hematopoietic stem cells are gaining added awareness and prevalence.They are primarily utilized for treating a varied range of blood-, metabolic-, bone-, and immune system-related disorders and diseases.

Moreover, the knowledge regarding the importance of the umbilical cord, as well as its applications, especially across developed markets, is steadily increasing.

REGIONAL INSIGHTS The global stem cell market growth analysis includes the Asia Pacific, Europe, North America, and the rest of the world.The Asia Pacific observes an increased incidence of chronic diseases, such as cancer, in addition to growing medical tourism in developing nations like India and China, as well as improved economic stability.

As a result, the region is anticipated to be the fastest-growing market for stem cells.

COMPETITIVE INSIGHTS Since stem cells play a crucial role in toxicology studies and drug discovery, the intensity towards optimizing the technical strength for stem cells is continually growing.This factor is also crucial in bolstering the growth of the companies operating in the market.

Hence, the degree of competitive rivalry is anticipated to increase further, and remain high, over the forecast period. The markets key players include, Corning Inc, Becton, Dickinson and Company (BD), GE Healthcare, Smith & Nephew PLC, Qiagen NV, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porters Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned 1. ALLCELLS LLC 2. BECTON, DICKINSON AND COMPANY (BD) 3. CORNING INC 4. CYTORI THERAPEUTICS 5. GE HEALTHCARE 6. INTERNATIONAL STEM CELL CORP 7. MERCK KGAA (SIGMA ALDRICH) 8. MILTENYI BIOTEC 9. PLURISTEM THERAPEUTICS INC 10. QIAGEN NV 11. SMITH & NEPHEW PLC 12. STEMCELL TECHNOLOGIES 13. STRYKER CORPORATION 14. TAKARA HOLDINGS INC 15. THERMO FISHER SCIENTIFIC INC Read the full report: https://www.reportlinker.com/p05478235/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continue reading here:
GLOBAL STEM CELL MARKET FORECAST 2021-2028 - GlobeNewswire

Stem Cell Therapy Market 2020 to 2025: Business Development Strategies and Top Manufacturers Analysis : Anterogen Co., Ltd. (South Korea), MEDIPOST…

Global Stem Cell Therapy Market Research Report 2020 to 2026 segmented by product type, applications and offers complete details including recent trends, statistics, and growth factors. An in-depth study of leading market players, supply chain scenario, business strategies and development scenario is presented in this report. Various factors like growth scenario, value chain analysis, deployment status and Stem Cell Therapy industry landscape scenario are presented in this report. The forecast information related to Global Stem Cell Therapy industry scenario is portrayed in this report. Stem Cell Therapy Market report depicts the forecast details to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns.

Request Free Sample Report of Stem Cell Therapy Market Report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=PT

For in-depth analysis and thorough understanding, the report presents a demand for individual segment in each region. It demonstrates various segments B2B, B2C, C2C and sub-segments Manufacturing, Consumer Goods, Retail, Automotive, Food and Beverage, Other of the global Stem Cell Therapy market. The global Stem Cell Therapy market report explains in-depth about the quantitative as well as the qualitative scenario of the market. The global Stem Cell Therapy market report delivers the precise analytical information that explains the future growth trend to be followed by the global Stem Cell Therapy market, based on the past and current situation of the market. In addition, the global Stem Cell Therapy market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. The situation of the global market at the global and regional level is also described in the global Stem Cell Therapy market report through geographical segmentation.

The research on the Stem Cell Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Stem Cell Therapy market on the basis of end user, product type, application, and demography for the forecast period 2020-2025. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics. This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Stem Cell Therapy market.

Browse complete Stem Cell Therapy report description and TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=PT

Global Stem Cell Therapy market is segmented based by type, application and region. Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on Application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Stem Cell Therapy Market research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges. The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used expert techniques for analyzing the Stem Cell Therapy Market; it also offers an examination of the global market. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

The research report on the global Stem Cell Therapy market offers a comprehensive analysis, synthesis, and interpretation of data gathered about the Stem Cell Therapy market from the number of reliable sources. In addition, the information has analyzed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Stem Cell Therapy market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Stem Cell Therapy market historically. The report provides a broad segmentation of the market by categorizing the market into application, type, and geographical regions. The Stem Cell Therapy market report delivers the growth prospects as well as the current scenario of the market. In addition, to assess the market size, the global Stem Cell Therapy market report offers a brief outlook of the market by synthesis, study, and addition of data form the number of sources.

The research provides answers to the following key questions: What will be the size of the market and the growth rate for the forecast period? 2020- 2027? Which key driving forces will keep create more opportunities for the Stem Cell Therapy market in years to come? Which are the most prominent players operating in the Stem Cell Therapy market? What have been their winning strategies so far? Which trends from the yesteryears or the future are likely to shape the progress of the Stem Cell Therapy market across different regions? What are the threats and challenges that can act like a barrier and restrict the development of the Stem Cell Therapy market? What are the future opportunities for prominent market players?

Major highlights of the report: All-inclusive evaluation of the parent market Evolution of significant market aspects -Industry-wide investigation of market segments Assessment of market value and volume in past, present, and forecast years Evaluation of market share Study of niche industrial sectors Tactical approaches of market leaders Lucrative strategies to help companies strengthen their position in the market

For More Information or Query or Customization Before Buying, Visit at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=PT

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more:
Stem Cell Therapy Market 2020 to 2025: Business Development Strategies and Top Manufacturers Analysis : Anterogen Co., Ltd. (South Korea), MEDIPOST...

Flow Cytometry Market Is Expected to Generate Revenue of US$ 11.3 billion by 2030, Globally – GlobeNewswire

November 11, 2020 14:30 ET | Source: insightSLICE

PUNE, India, Nov. 11, 2020 (GLOBE NEWSWIRE) -- The Global Flow Cytometry Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis.

The Global Flow Cytometry Market size was estimated to be US$ 4.7 billion in 2019 and is expected to reach US$ 11.3 billion by 2030. It has ascended as an essential device for security and exploratory objectives during drug detection and advancement methods. The method assists to sub-classify cell types to pick the best therapy program. It can also recognize the remaining levels of illness after therapy. Technological capability to examine a large number of particles in a short time period to render statistically sound data about the cell population is one of the main reasons for its evolution as an essential device. Further, its multi-parametric methodology is also helping the acceptance of flow cytometry in drug detection and advancement methods. Moreover, major factors that are driving the market consist of the surge in the application of flow cytometry in stem cell research, the arrival and commercial use of innovative technologies in the field of flow cytometry, and escalation in the applications of flow cytometry in clinical research. Additionally, rising consciousness and improved healthcare expenses are probable to have an optimistic effect on the flow cytometry market.

View This Report with Table of Contents : https://www.insightslice.com/flow-cytometry-market

The commercial organization end-use segment is anticipated to hold the major income share

The global flow cytometry market is segmented on the basis of technology, product & services, application, end-use, and geography. Based on technology the market is segmented into cell-based and bead-based. By product & services the market is divided into instruments, reagent & consumables, software, accessories, and services. Depending on the application segment the flow cytometry market is divided into research, industrial, and clinical. On the basis of end-use the market is classified into commercial organizations, hospitals, academic institutes, clinical testing labs. The commercial organization segment apprehended the uppermost market share in 2019 as a result of wide range of applications across different sectors including food microbiology, blood banks, and plant cell structure. The introduction of multiplex probes and reagents for specific applications in diagnostics and drug detection is anticipated to give several growth opportunities for the segment by catering to the users in research and small peripheral labs.

Access The Sample Pages of This Report : https://www.insightslice.com/request-sample/494

Based on geography, the global Flow Cytometry Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, the United Kingdom, Belgium, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Indonesia, Australia, South Korea, Taiwan, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, the UAE, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

North America headed the flow cytometry market in 2019 due to the existence of helpful government restructurings for the growth of innovative technologies for molecular diagnostics. It likely to uphold dominance over the forecast years as a result of the accessibility of trained specialists and greater consciousness levels.

Related report :

Global Healthcare Fabrics Market : https://www.insightslice.com/healthcare-fabrics-market

Global Cold Laser Therapy Market : https://www.insightslice.com/cold-laser-therapy-market

Global Resuscitation Devices Market : https://www.insightslice.com/resuscitation-devices-market

The APAC region is anticipated to experience rapid growth in the imminent year thanks to the reassuring government finance for the biotech business improvement. Additionally, the existence of unused opportunities, continuously refining healthcare substructure, accelerated financial growth, and growing patient consciousness levels are further projected to boost the local market. Incessant R&D projects for cancer cure in the region, facilitating the demand for cytometry, is further propelling the regions market expansion. Besides, the increasing acceptance of new procedures for molecular-based cytogenetics, growing subcontracting ventures, and rising demand for initial diagnosis and recognition of illnesses will drive the market in the APAC region.

Major players active in the global flow cytometry market are GE Healthcare, Beckman Coulter, Inc., Stratedigm, Inc., Becton, Sysmex Corporation, Merck & Co., Inc., Luminex Corporation, Apogee Flow Systems Ltd., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Miltenyi Biotec, Agilent Technologies, and Dickinson and Company.

Buy This Report : https://www.insightslice.com/buy-now/494

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details please contact our research and consulting team at info@insightslice.com.

Contact Us:

Alex,

insightSLICE

Phone (USA) : +1 707 736 6633 Email address : alex@insightslice.com

Web: http://www.insightslice.com

See original here:
Flow Cytometry Market Is Expected to Generate Revenue of US$ 11.3 billion by 2030, Globally - GlobeNewswire

ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights – BioSpace

Nov. 12, 2020 12:00 UTC

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

The third quarter was one of tremendous execution as we prepare for the U.S. launch of our first drug, Lonca, for the treatment of relapsed or refractory diffuse large B-cell lymphoma, said Chris Martin, Chief Executive Officer of ADC Therapeutics. We have submitted our Biologics License Application to the U.S. Food and Drug Administration and are now working diligently to prepare for a planned commercial launch in mid-2021, including U.S. organizational build-out, the establishment of U.S. operations to ensure distribution, access and reimbursement of Lonca, and significant appropriate physician engagement. In addition to our commercial preparations, we are expanding our Lonca development activities, having initiated our Phase 3 LOTIS 5 clinical trial evaluating Lonca in combination with rituximab as a second-line therapy in DLBCL and are preparing to initiate our Phase 2 trial of Lonca in follicular lymphoma next year.

Dr. Martin continued, Across our Cami programs, we have now enrolled more than half of the 100-patient pivotal Phase 2 trial in Hodgkin lymphoma and continue to see promising preliminary data from our Phase 1b trial in solid tumors that show robust immune activity following treatment, as well as recently published preclinical data highlighting the anti-tumor activity of CD25-targeted antibody drug conjugates. With these promising data, we expanded our Phase 1b trial to evaluate Cami in combination with pembrolizumab to better understand its potential as both a monotherapy and in combination and have dosed the first patient in the combination arm. To support these exciting developments and ensure continued growth across our pipeline, we completed an upsized public offering in September. With these additional funds, we look forward to continuing to deliver on our vision to bring transformative therapies to cancer patients as quickly and effectively as possible.

Recent Clinical and Business Highlights:

Anticipated Upcoming Milestones:

Third Quarter 2020 Financial Results

Cash and Cash Equivalents

Cash and cash equivalents were $494.4 million as of September 30, 2020, compared to $115.6 million as of December 31, 2019.

Research and Development (R&D) Expenses

R&D expenses were $32.2 million for the quarter ended September 30, 2020, compared to $30.5 million for the same quarter in 2019. The increase was primarily due to increased share-based compensation expense.

General and Administrative (G&A) Expenses

G&A expenses were $20.3 million for the quarter ended September 30, 2020, compared to $2.3 million for the same quarter in 2019. The increase was primarily due to an increased number of Commercial employees, increased costs due to new commercial activities and increased share-based compensation expense.

Net Loss and Adjusted Net Loss

Net loss was $20.3 million, or a net loss of $0.29 per basic and diluted share, for the quarter ended September 30, 2020, compared to $31.3 million, or a net loss of $0.62 per basic and diluted share, for the same quarter in 2019. The net loss for the quarter ended September 30, 2020 includes a $33.9 million non-cash gain related to the changes in fair value of derivatives associated with the convertible loans under the Convertible Credit Facility with Deerfield. The decrease in fair value was driven by the decrease in the Companys share price from June 30, 2020. In addition, net loss included share-based compensation expense of $11.0 million for the quarter ended September 30, 2020, compared to $0.2 million for the same quarter in 2019.

Adjusted net loss was $41.3 million, or an adjusted net loss of $0.58 per basic and diluted share, for the quarter ended September 30, 2020, compared to $31.1 million, or an adjusted net loss of $0.62 per basic and diluted share, for the same quarter in 2019. The increase in adjusted net loss was primarily driven by higher employee headcount across the organization and costs associated with the build out of the Companys commercial organization in preparation for the anticipated launch of Lonca in 2021.

Conference Call Details

ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2020 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the call, please dial +41 225 675632 (international) or (833) 249-8403 (U.S.). A live webcast of the presentation will be available on the Investors section of the ADC Therapeutics website at http://www.ir.adctherapeutics.com. The archived webcast will be available after the completion of the event.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the Companys lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. In September 2020, ADC Therapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval for Lonca for the treatment of patients with relapsed or refractory DLBCL. Camidanlumab tesirine (Cami, formerly ADCT-301), the Companys second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown in a Phase 1 clinical trial an 86.5% ORR in HL patients at the dose selected for Phase 2. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

Use of Non-IFRS Financial Measures

In addition to financial information prepared in accordance with IFRS, this document also contains certain non-IFRS financial measures based on managements view of performance including:

Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-IFRS measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with IFRS. When preparing these supplemental non-IFRS measures, management typically excludes certain IFRS items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these IFRS items to be normal, recurring cash or non-cash operating expenses; however, these items may not meet the IFRS definition of unusual or non-recurring items. Since non-IFRS financial measures do not have standardized definitions and meanings, they may differ from the non-IFRS financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other IFRS financial measures.

The following items are excluded from adjusted net loss and adjusted net loss per share:

Shared-Based Compensation Expense: We exclude share-based compensation from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

Certain Other Items: We exclude certain other significant items that may occur occasionally and are not normal, recurring operating expenses, cash or non-cash, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature and generally represent items that, either as a result of their nature or significance, management would not anticipate occurring as part of our normal business on a regular basis. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be: changes in the fair value of derivatives, and the effective interest expense, associated with the Convertible Credit Facility with Deerfield, as well as transaction costs associated with debt or equity issuances that are expensed pursuant to IFRS.

See the attached Reconciliation of IFRS Measures to Non-IFRS Measures for explanations of the amounts excluded and included to arrive at the non-IFRS financial measures for the three- and nine-month periods ended September 30, 2020 and 2019.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our managements beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

ADC Therapeutics SA

Condensed Consolidated Interim Statement of Operations (Unaudited)

(in KUSD except for share and per share data)

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2020

2019

2020

2019

-

-

-

2,340

(32,155

)

(30,541

)

(93,480

)

(77,113

)

(20,273

)

(2,302

)

(47,782

)

(8,894

)

(52,428

)

(32,843

)

(141,262

)

(86,007

)

(52,428

)

(32,843

)

(141,262

)

(83,667

)

145

1,433

423

1,433

33,868

-

(45,393

)

-

More:
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights - BioSpace

Stem Cell Characterization and Analysis Tool Market Size Analysis: Growth Factors, Share by Regional Production, Revenue and Regional Trends with Key…

Global Stem Cell Characterization and Analysis Tool Market 2020 report consists of important factors such as the latest trends, performance drivers, key players, revenue, growth rate and volume sales, and consumer insights. The report Stem Cell Characterization and Analysis Tool Market gives detailed information on enterprises on a global and regional level through an all-inclusive analysis and insights into developments affecting businesses. It accommodates an entire overview of the market, including the market size, share, and the projection of this global market, within a specific interval of time. Then, it covers the major players functioning in Stem Cell Characterization and Analysis Tool market.

Get a Sample PDF of Report https://www.marketreportsworld.com/enquiry/request-sample/16070853

The Global Stem Cell Characterization and Analysis Tool market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Characterization and Analysis Tool market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

To Understand How COVID-19 Impact is Covered in this Report. Get Sample Copy of the report at-

https://www.marketreportsworld.com/enquiry/request-covid19/16070853

The research covers the current Stem Cell Characterization and Analysis Tool market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

About Stem Cell Characterization and Analysis Tool Market:

Stem cell characterization is the study of tissue-specific differentiation. There are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases.Market Analysis and Insights: Global Stem Cell Characterization and Analysis Tool MarketThe global Stem Cell Characterization and Analysis Tool market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell Characterization and Analysis Tool market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell Characterization and Analysis Tool market in terms of revenue.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell Characterization and Analysis Tool market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell Characterization and Analysis Tool market.Global Stem Cell Characterization and Analysis Tool Scope and Market SizeStem Cell Characterization and Analysis Tool market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cell Characterization and Analysis Tool market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.Market segment by Type, the product can be split into Services Software Instruments Accessories Consumables Reagent and Assay KitsMarket segment by Application, split into Neurological Disorders Orthopedic Treatments Oncology Disorders Diabetes Other Therapeutic Applications Drug Development and Discovery Embryonic Stem Cells ResearchBased on regional and country-level analysis, the Stem Cell Characterization and Analysis Tool market has been segmented as follows: North America United States Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Latin America Mexico Brazil Middle East & Africa Turkey Saudi Arabia UAE Rest of Middle East & AfricaIn the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell Characterization and Analysis Tool market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this study Osiris Therapeutics, Inc. Caladrius Biosciences, Inc. U.S. Stem Cell, Inc. Astellas Pharma Inc. TEMCELL Technologies Inc. BioTime Inc. Cellular Engineering Technologies Inc. Cytori Therapeutics, Inc. BrainStorm Cell Therapeutics Inc.

This report focuses on the Stem Cell Characterization and Analysis Tool in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Stem Cell Characterization and Analysis Tool Market Report 2020

Report further studies the market development status and future Stem Cell Characterization and Analysis Tool Market trend across the world. Also, it splits Stem Cell Characterization and Analysis Tool Market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Characterization and Analysis Tool in these regions, from 2015 to 2026, covering

This Stem Cell Characterization and Analysis Tool Market Research/Analysis Report Contains Answers to your following Questions

Enquire Before Purchasing This Report at

https://www.marketreportsworld.com/enquiry/pre-order-enquiry/16070853

Major Points from Table of Contents:

1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Stem Cell Characterization and Analysis Tool Market Size Growth Rate by Type: 2020 VS 2026 1.2.2 Services 1.2.3 Software 1.2.4 Instruments 1.2.5 Accessories 1.2.6 Consumables 1.2.7 Reagent and Assay Kits 1.3 Market by Application 1.3.1 Global Stem Cell Characterization and Analysis Tool Market Share by Application: 2020 VS 2026 1.3.2 Neurological Disorders 1.3.3 Orthopedic Treatments 1.3.4 Oncology Disorders 1.3.5 Diabetes 1.3.6 Other Therapeutic Applications 1.3.7 Drug Development and Discovery Embryonic Stem Cells Research 1.4 Study Objectives 1.5 Years Considered

2 Global Growth Trends 2.1 Global Stem Cell Characterization and Analysis Tool Market Perspective (2015-2026) 2.2 Global Stem Cell Characterization and Analysis Tool Growth Trends by Regions 2.2.1 Stem Cell Characterization and Analysis Tool Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Stem Cell Characterization and Analysis Tool Historic Market Share by Regions (2015-2020) 2.2.3 Stem Cell Characterization and Analysis Tool Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Market Restraints

3 Competition Landscape by Key Players 3.1 Global Top Stem Cell Characterization and Analysis Tool Players by Market Size 3.1.1 Global Top Stem Cell Characterization and Analysis Tool Players by Revenue (2015-2020) 3.1.2 Global Stem Cell Characterization and Analysis Tool Revenue Market Share by Players (2015-2020) 3.2 Global Stem Cell Characterization and Analysis Tool Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Stem Cell Characterization and Analysis Tool Revenue 3.4 Global Stem Cell Characterization and Analysis Tool Market Concentration Ratio 3.4.1 Global Stem Cell Characterization and Analysis Tool Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Stem Cell Characterization and Analysis Tool Revenue in 2019 3.5 Key Players Stem Cell Characterization and Analysis Tool Area Served 3.6 Key Players Stem Cell Characterization and Analysis Tool Product Solution and Service 3.7 Date of Enter into Stem Cell Characterization and Analysis Tool Market 3.8 Mergers & Acquisitions, Expansion Plans

4 Stem Cell Characterization and Analysis Tool Breakdown Data by Type (2015-2026) 4.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Type (2015-2020) 4.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Type (2021-2026)

5 Stem Cell Characterization and Analysis Tool Breakdown Data by Application (2015-2026) 5.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Application (2015-2020) 5.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Application (2021-2026)

6 North America 6.1 North America Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 6.2 North America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 6.3 North America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 6.4 North America Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 6.4.1 United States 6.4.2 Canada

7 Europe 7.1 Europe Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 7.2 Europe Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 7.3 Europe Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 7.4 Europe Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 7.4.6 Nordic 7.4.7 Rest of Europe

8 China 8.1 China Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 8.2 China Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 8.3 China Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 8.4 China Stem Cell Characterization and Analysis Tool Market Size by Region (2015-2020) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 Southeast Asia 8.4.5 India 8.4.6 Australia 8.4.7 Rest of Asia-Pacific

9 Japan 9.1 Japan Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 9.2 Japan Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 9.3 Japan Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 9.4 Japan Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 9.4.1 Mexico 9.4.2 Brazil

10 Southeast Asia 10.1 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 10.2 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 10.3 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 10.4 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles 11.1 Osiris Therapeutics, Inc. 11.1.1 Osiris Therapeutics, Inc. Company Details 11.1.2 Osiris Therapeutics, Inc. Business Overview 11.1.3 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.1.4 Osiris Therapeutics, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020)) 11.1.5 Osiris Therapeutics, Inc. Recent Development 11.2 Caladrius Biosciences, Inc. 11.2.1 Caladrius Biosciences, Inc. Company Details 11.2.2 Caladrius Biosciences, Inc. Business Overview 11.2.3 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.2.4 Caladrius Biosciences, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.2.5 Caladrius Biosciences, Inc. Recent Development 11.3 U.S. Stem Cell, Inc. 11.3.1 U.S. Stem Cell, Inc. Company Details 11.3.2 U.S. Stem Cell, Inc. Business Overview 11.3.3 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.3.4 U.S. Stem Cell, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.3.5 U.S. Stem Cell, Inc. Recent Development 11.4 Astellas Pharma Inc. 11.4.1 Astellas Pharma Inc. Company Details 11.4.2 Astellas Pharma Inc. Business Overview 11.4.3 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Introduction 11.4.4 Astellas Pharma Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.4.5 Astellas Pharma Inc. Recent Development 11.5 TEMCELL Technologies Inc. 11.5.1 TEMCELL Technologies Inc. Company Details 11.5.2 TEMCELL Technologies Inc. Business Overview 11.5.3 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Introduction 11.5.4 TEMCELL Technologies Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.5.5 TEMCELL Technologies Inc. Recent Development 11.6 BioTime Inc. 11.6.1 BioTime Inc. Company Details 11.6.2 BioTime Inc. Business Overview 11.6.3 BioTime Inc. Stem Cell Characterization and Analysis Tool Introduction 11.6.4 BioTime Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.6.5 BioTime Inc. Recent Development 11.7 Cellular Engineering Technologies Inc. 11.7.1 Cellular Engineering Technologies Inc. Company Details 11.7.2 Cellular Engineering Technologies Inc. Business Overview 11.7.3 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Introduction 11.7.4 Cellular Engineering Technologies Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.7.5 Cellular Engineering Technologies Inc. Recent Development 11.8 Cytori Therapeutics, Inc. 11.8.1 Cytori Therapeutics, Inc. Company Details 11.8.2 Cytori Therapeutics, Inc. Business Overview 11.8.3 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.8.4 Cytori Therapeutics, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.8.5 Cytori Therapeutics, Inc. Recent Development 11.9 BrainStorm Cell Therapeutics Inc. 11.9.1 BrainStorm Cell Therapeutics Inc. Company Details 11.9.2 BrainStorm Cell Therapeutics Inc. Business Overview 11.9.3 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Introduction 11.9.4 BrainStorm Cell Therapeutics Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.9.5 BrainStorm Cell Therapeutics Inc. Recent Development

12 Analysts Viewpoints/Conclusions

13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

Purchase this report (Price 3900 USD for a single user license)

https://www.marketreportsworld.com/purchase/16070853

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:[emailprotected]

Phone:US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Lemon Essential Oil Battery Market Size 2020 Business Strategies, Opportunities, Future Trends, Top Key Players, Market Share, and Forecast 2023

Garden Tillers Market Size, Share 2020 Global Industry Trends, Sales Revenue, Industry Growth, Development Status, Top Leaders, Future Plans and Opportunity Assessment 2026

Global Microgrid Market Size, Share 2020|Global Industry by Growth Insight, Key Development, Trends, Business Anaslysis, and Forecast by Market Reports World

Epoxy Polyester Powder Coatings Market Size, Share 2020 Explosive Factors of Revenue by Key Vendors, Demand, Development Strategy, Future Trends and Industry Growth Research Report

Global Isotopes Market 2020 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications by Market Research Report to 2025

Pizza Ovens for Commercial Use Market Size, Share Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2026

Telescope and Hand-held Later Rangefinder Market 2020 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2026

Music Production Software Market Size, Share 2020 Global Industry Demand, Recent Trends, Estimation by 2023 with Top Players MarketReportsWorld.com

Swine Feed Premix Market 2020 Global Industry Share, Size, Future Demand, Global Research, Top Leading Players, Emerging Trends, Region by Forecast to 2023

Laboratory Stability Test Chambers Market Size, Share 2020 Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2026

Originally posted here:
Stem Cell Characterization and Analysis Tool Market Size Analysis: Growth Factors, Share by Regional Production, Revenue and Regional Trends with Key...

Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update – Galveston County Daily News

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 12, 2020--

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the third quarter ended September 30, 2020. The company also highlighted recent progress and upcoming milestones for its pipeline programs.

We are very pleased with our strong pipeline progress during the quarter amid such challenging times, said Frank Lee, President and Chief Executive Officer of Forma. We look forward to presenting new data from our ongoing Phase 1 trial of FT-4202 in sickle cell disease at the ASH meeting in December, as well as beginning enrollment of patients for our Phase 1 trial of FT-7051 in men living with metastatic castration-resistant prostate cancer. The recent positive top-line results from the olutasidenib registrational Phase 2 clinical trial in relapsed/refractory acute myeloid leukemia with an IDH1 mutation further underscores our commitment to developing transformative therapies for patients.

Key Business and Clinical Highlights

PKR Program in Sickle Cell Disease (SCD):

CPB/p300 Program in Prostate Cancer:

IDH1 Program in AML and Glioma:

Corporate:

Upcoming Milestones

Upcoming Investor Events

Financial Results

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit http://www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the companys beliefs and expectations regarding its: business plans and objectives; future plans for FT-4202 and FT-7051, including expectations regarding timing and success of the current ongoing clinical trials, therapeutic potential and clinical benefits thereof, and upcoming milestones for the companys other product candidates; growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress; presentation of additional data at upcoming scientific conferences, and other preclinical data in 2020; the potential commercial and collaboration opportunities, including potential future collaborators and parties, as well as value and market, for our product candidates; uses of capital, expenses and other 2020 financial results or in the future, and the potential impact of COVID-19 on patient retention, strategy, future operations, clinical trials or IND submissions. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on the companys business, operations, strategy, goals and anticipated milestones; the therapeutic potential of FT-4202, and the timing associated with the initiation or continuation of any of FT-4202 trials; the initiation of our phase I clinical trial of FT-7051; Formas ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Formas ability to fund operations; Formas ability to identify satisfactory collaboration opportunities, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the final prospectus dated June 22, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Formas filings and reports with the SEC. Forma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Formas views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Forma explicitly disclaims any obligation to update any forward-looking statements.

2020

2019

2020

2019

$ -

$ 3,377

$ -

$ 93,113

24,780

27,558

68,501

84,273

7,460

7,025

22,841

17,631

-

545

63

5,620

32,240

35,128

91,405

107,524

(32,240)

(31,751)

(91,405)

(14,411)

818

766

23,050

3,057

(31,422)

(30,985)

(68,355)

(11,354)

(3,806)

-

(26,529)

(1,217)

$ (27,616)

$ (30,985)

$ (41,826)

$ (10,137)

-

(607)

(3,736)

(2,395)

-

-

-

(11,347)

-

(60)

-

(60)

$ (27,616)

$ (45,562)

(8)

-

$ (27,624)

$ (45,562)

$ (31,652)

$ (23,939)

(198)

(515)

$ (31,850)

$ (24,454)

$ (0.67)

$ (2.74)

$ (0.67)

$ (2.74)

$ (12.42)

$ (9.40)

$ (12.50)

$ (9.60)

41,088,261

16,616,143

41,088,924

16,616,143

2,547,924

Read the original here:
Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Galveston County Daily News

Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – BCFocus

Data Bridge Market Research has recently published the Global research Report TitledAdipose Tissue-Derived Stem Cells (ADSCS) Market.

TheAdipose Tissue-Derived Stem Cells (ADSCS) Marketreport gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take upmarket research report service which has become enough vital in todays market place.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

This report examines all the key factors influencing the growth of Adipose Tissue-Derived Stem Cells (ADSCS) market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Adipose Tissue-Derived Stem Cells (ADSCS) market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

Get Free Sample Copy of the Report to Understand the Structure of the Complete Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

The Global Adipose Tissue-Derived Stem Cells (ADSCS) Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Adipose Tissue-Derived Stem Cells (ADSCS) market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Adipose Tissue-Derived Stem Cells (ADSCS) Market in each region. Various methodological tools are used to analyze the growth of the worldwide Adipose Tissue-Derived Stem Cells (ADSCS) market.

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

How Does This Market Insights Help?

Key Pointers Covered in the Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry Trends and Forecast

Reasons to Purchase this Report

Request Free Sample PDF (including COVID19 Impact Analysis) of Adipose Tissue-Derived Stem Cells (ADSCS) MarketReport@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Market Dynamics:The Adipose Tissue-Derived Stem Cells (ADSCS) report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - BCFocus

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results – PRNewswire

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

"This quarter, our Company reached a significant milestone by initiating our first Marker-sponsored studya Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia," said Peter L. Hoang, President & CEO of Marker Therapeutics. "We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process of scheduling the donor in order to manufacture the product."

Continued Mr. Hoang: "During this unprecedented time, we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process, reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones."

PROGRAM UPDATES

MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML

Phase 2 AML Trial The Company initiated the safety lead-in portion of its Phase 2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier.

Marker has activated four clinical sites and is in the start-up phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites.

The study remains on partial clinical hold pending the review of final data and subsequent acceptance of certificates of analysis for the new reagent by the U.S. FDA. The Company received the remaining reagent from the alternate supplier in Q3 2020 and is currently conducting the comparability analyses between the previous and new reagents, as required by FDA. Marker intends to submit all required data to FDA by Q1 2021 to enable removal of the partial clinical hold.

Over the past year, the Company has continued to streamline and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 95% reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration. The Company expects the new process to yield a measurably improved product, with superior T cell phenotype and antigen specificity as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used for all patients in the Marker AML clinical trial.

BUSINESS UPDATES

THIRD QUARTER 2020 FINANCIAL RESULTS

Cash Position and Guidance:At September 30, 2020, Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital along with current cash available, funds operations into Q1 2022.

R&D Expenses:Research and development expenses were$4.8 million for the quarter endedSeptember 30, 2020, compared to$3.1 million for the quarter ended September 30, 2019.

G&A Expenses:General and administrative expenses were$2.6 million for the quarter endedSeptember 30, 2020, compared to $2.5 million for the quarter ended September 30, 2019.

Net Loss:Marker reported a net loss of$7.4 millionfor the quarter endedSeptember 30, 2020, compared to a net loss of$5.5 million for the quarter ended September 30, 2019.

Conference Call and Webcast

The Company will host a webcast and conference call to discuss its third quarter 2020 financial results and provide a corporate update today at 5:00 PM EST.

The webcast will be accessible in theInvestorssection of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics Third Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Marker website following the event.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the timing, conduct and success of our clinical trials, as well as clinical trials conducted by our collaborators; our manufacturing processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.

Condensed Consolidated Balance Sheets

September 30,

December 31,

2020

2019

(Unaudited)

(Audited)

ASSETS

Current assets:

Cash and cash equivalents

$ 26,956,737

$ 43,903,949

Prepaid expenses and deposits

2,367,145

1,526,442

Interest receivable

135

56,189

Other receivable

1,000,000

-

Total current assets

30,324,017

45,486,580

Non-current assets:

Property, plant and equipment, net

2,629,628

417,528

Construction in progress

4,557,581

-

Right-of-use assets, net

11,059,962

455,174

Total non-current assets

18,247,171

872,702

Total assets

$ 48,571,188

$ 46,359,282

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$ 5,746,149

$ 1,757,680

Lease liability

278,333

204,132

Warrant liability

-

31,000

Total current liabilities

6,024,482

1,992,812

Non-current liabilities:

Lease liability, net of current portion

11,948,781

280,247

Total non-current liabilities

11,948,781

280,247

Total liabilities

17,973,263

2,273,059

Commitments and contingencies

-

-

Stockholders' equity:

Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

-

-

Common stock, $0.001 par value, 150 million shares authorized, 48.0 million and 45.7 million shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

48,025

45,728

Additional paid-in capital

378,282,157

371,573,909

Go here to see the original:
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - PRNewswire